{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:17:55Z","timestamp":1790813875196,"version":"4.1.0"},"reference-count":147,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T00:00:00Z","timestamp":1532908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer cachexia affects most patients with advanced forms of cancers. It is mainly characterized by weight loss, due to muscle and adipose mass depletion. As cachexia is associated with increased morbidity and mortality in cancer patients, identifying the underlying mechanisms leading to cachexia is essential in order to design novel therapeutic strategies. The mechanistic target of rapamycin (mTOR) is a major intracellular signalling intermediary that participates in cell growth by upregulating anabolic processes such as protein and lipid synthesis. Accordingly, emerging evidence suggests that mTOR and mTOR inhibitors influence cancer cachexia. Here, we review the role of mTOR in cellular processes involved in cancer cachexia and highlight the studies supporting the contribution of mTOR in cancer cachexia.<\/jats:p>","DOI":"10.3390\/ijms19082225","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T11:55:08Z","timestamp":1532951708000},"page":"2225","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["mTOR and Tumor Cachexia"],"prefix":"10.3390","volume":"19","author":[{"given":"Adrian P.","family":"Duval","sequence":"first","affiliation":[{"name":"Department of Visceral Surgery, Lausanne University Hospital, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Jeanneret","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Lausanne University Hospital, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Lausanne University Hospital, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-1782","authenticated-orcid":false,"given":"Olivier","family":"Dormond","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Lausanne University Hospital, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"61","article-title":"Causes of death in cancer patients","volume":"6","author":"Ambrus","year":"1975","journal-title":"J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/1097-0142(197402)33:2<568::AID-CNCR2820330236>3.0.CO;2-2","article-title":"Proceedings: Causes of death in cancer patients","volume":"33","author":"Inagaki","year":"1974","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s11605-008-0505-z","article-title":"Cachexia worsens prognosis in patients with resectable pancreatic cancer","volume":"12","author":"Bachmann","year":"2008","journal-title":"J. Gastrointest. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"Mtor signalling in growth, metabolism and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fphys.2017.00788","article-title":"Mtor as a key regulator in maintaining skeletal muscle mass","volume":"8","author":"Yoon","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1101\/gad.276733.115","article-title":"Mechanisms of metabolic dysfunction in cancer-associated cachexia","volume":"30","author":"Petruzzelli","year":"2016","journal-title":"Genes Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/MCO.0b013e3282f9ae4d","article-title":"Computational modeling of cancer cachexia","volume":"11","author":"Hall","year":"2008","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: Mediators, signalling and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mueller, T.C., Bachmann, J., Prokopchuk, O., Friess, H., and Martignoni, M.E. (2016). Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia\u2014Can findings from animal models be translated to humans?. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2121-8"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1006961919775","article-title":"Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia","volume":"26","author":"Attaix","year":"1999","journal-title":"Mol. Biol. Rep."},{"key":"ref_15","first-page":"E332","article-title":"A new model of cancer cachexia: Contribution of the ubiquitin-proteasome pathway","volume":"277","author":"Lazarus","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/sj.bjc.6602780","article-title":"Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia","volume":"93","author":"Khal","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1023\/A:1006955832323","article-title":"Manipulation of the ubiquitin-proteasome pathway in cachexia: Pentoxifylline suppresses the activation of 20s and 26s proteasomes in muscles from tumour-bearing rats","volume":"26","author":"Combaret","year":"1999","journal-title":"Mol. Biol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00432-013-1412-6","article-title":"Mg132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia","volume":"139","author":"Zhang","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0039-6060(99)70131-5","article-title":"The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer","volume":"126","author":"Williams","year":"1999","journal-title":"Surgery"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"R1518","DOI":"10.1152\/ajpregu.2001.280.5.R1518","article-title":"Increased muscle ubiquitin mrna levels in gastric cancer patients","volume":"280","author":"Bossola","year":"2001","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_21","first-page":"257","article-title":"Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia","volume":"14","author":"DeJong","year":"2005","journal-title":"Oncol. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1042\/cs1020353","article-title":"Skeletal muscle mrna levels for cathepsin b, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy","volume":"102","author":"Jagoe","year":"2002","journal-title":"Clin. Sci. (Lond.)"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2011.09.012","article-title":"Pre-cachexia in patients with stages i\u2013iii non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system","volume":"76","author":"Langen","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ajpath.2012.12.023","article-title":"Autophagic degradation contributes to muscle wasting in cancer cachexia","volume":"182","author":"Penna","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1074\/jbc.M610378200","article-title":"Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation","volume":"282","author":"Eley","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_26","first-page":"2779","article-title":"Protein synthesis measured in vivo in muscle and liver of cachectic tumour-bearing mice","volume":"44","author":"Emery","year":"1984","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/bmj.289.6445.584","article-title":"Protein synthesis in muscle measured in vivo in cachectic patients with cancer","volume":"289","author":"Emery","year":"1984","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ncb1101-1009","article-title":"Mediation of igf-1-induced skeletal myotube hypertrophy by pi(3)k\/akt\/mtor and pi(3)k\/akt\/gsk3 pathways","volume":"3","author":"Rommel","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-007-0177-2","article-title":"Activity of the akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia","volume":"85","author":"Schmitt","year":"2007","journal-title":"J. Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jcsm.12005","article-title":"Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients","volume":"6","author":"Stephens","year":"2015","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/ijc.25146","article-title":"Muscle atrophy in experimental cancer cachexia: Is the igf-1 signalling pathway involved?","volume":"127","author":"Penna","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"H466","DOI":"10.1152\/ajpheart.00720.2015","article-title":"The pathogenesis and treatment of cardiac atrophy in cancer cachexia","volume":"310","author":"Murphy","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3892\/ijo.2013.1893","article-title":"Altered cardiac muscle mtor regulation during the progression of cancer cachexia in the apcmin\/+ mouse","volume":"42","author":"Manne","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_34","first-page":"1321","article-title":"Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice","volume":"39","author":"Tian","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-10-3145","article-title":"Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner","volume":"71","author":"Cosper","year":"2011","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","article-title":"Prevention of liver cancer cachexia-induced cardiac wasting and heart failure","volume":"35","author":"Springer","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.3390\/nu6115280","article-title":"Evidence and mechanisms of fat depletion in cancer","volume":"6","author":"Ebadi","year":"2014","journal-title":"Nutrients"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.clnu.2009.11.006","article-title":"Loss of adipose tissue and plasma phospholipids: Relationship to survival in advanced cancer patients","volume":"29","author":"Murphy","year":"2010","journal-title":"Clin. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1002\/cncr.21013","article-title":"Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care\u2014Correlations with food intake, metabolism, exercise capacity and hormones","volume":"103","author":"Fouladiun","year":"2005","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/sj.bjc.6605665","article-title":"Adipose tissue pathways involved in weight loss of cancer cachexia","volume":"102","author":"Dahlman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1158\/0008-5472.CAN-06-4585","article-title":"Mechanism of increased lipolysis in cancer cachexia","volume":"67","author":"Agustsson","year":"2007","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/j.1349-7006.2010.01582.x","article-title":"Role of beta1-adrenoceptor in increased lipolysis in cancer cachexia","volume":"101","author":"Cao","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1126\/science.1198973","article-title":"Adipose triglyceride lipase contributes to cancer-associated cachexia","volume":"333","author":"Das","year":"2011","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6603360","article-title":"Adipose atrophy in cancer cachexia: Morphologic and molecular analysis of adipose tissue in tumour-bearing mice","volume":"95","author":"Bing","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","article-title":"A switch from white to brown fat increases energy expenditure in cancer-associated cachexia","volume":"20","author":"Petruzzelli","year":"2014","journal-title":"Cell Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature13528","article-title":"Tumour-derived pth-related protein triggers adipose tissue browning and cancer cachexia","volume":"513","author":"Kir","year":"2014","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tem.2016.06.006","article-title":"White adipose tissue browning: A double-edged sword","volume":"27","author":"Abdullahi","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11745-011-3630-5","article-title":"Low levels of lipogenic enzymes in peritumoral adipose tissue of colorectal cancer patients","volume":"47","author":"Notarnicola","year":"2012","journal-title":"Lipids"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/JOE-12-0307","article-title":"Heterogeneous time-dependent response of adipose tissue during the development of cancer cachexia","volume":"215","author":"Batista","year":"2012","journal-title":"J. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tsoli, M., Schweiger, M., Vanniasinghe, A.S., Painter, A., Zechner, R., Clarke, S., and Robertson, G. (2014). Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092966"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","article-title":"Raptor, a binding partner of target of rapamycin (tor), mediates tor action","volume":"110","author":"Hara","year":"2002","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1097-2765(03)00114-X","article-title":"Gbetal, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mtor","volume":"11","author":"Kim","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"Pras40 is an insulin-regulated inhibitor of the mtorc1 protein kinase","volume":"25","author":"Sancak","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","article-title":"Deptor is an mtor inhibitor frequently overexpressed in multiple myeloma cells and required for their survival","volume":"137","author":"Peterson","year":"2009","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","article-title":"Tbc1d7 is a third subunit of the tsc1-tsc2 complex upstream of mtorc1","volume":"47","author":"Dibble","year":"2012","journal-title":"Mol. Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","article-title":"Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway","volume":"10","author":"Manning","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cub.2005.02.053","article-title":"Rheb binds and regulates the mtor kinase","volume":"15","author":"Long","year":"2005","journal-title":"Curr. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"Tsc2 is phosphorylated and inhibited by akt and suppresses mtor signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"13489","DOI":"10.1073\/pnas.0405659101","article-title":"Tumor-promoting phorbol esters and activated ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal s6 kinase","volume":"101","author":"Roux","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"Tsc2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"Ampk phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1256804","article-title":"Regulation of mtor function in response to hypoxia by redd1 and the tsc1\/tsc2 tumor suppressor complex","volume":"18","author":"Brugarolas","year":"2004","journal-title":"Genes Dev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cell.2010.02.024","article-title":"Ragulator-rag complex targets mtorc1 to the lysosomal surface and is necessary for its activation by amino acids","volume":"141","author":"Sancak","year":"2010","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1157535","article-title":"The rag gtpases bind raptor and mediate amino acid signaling to mtorc1","volume":"320","author":"Sancak","year":"2008","journal-title":"Science"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2005.10.024","article-title":"Mtor and s6k1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events","volume":"123","author":"Holz","year":"2005","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.277.5322.99","article-title":"Phosphorylation of the translational repressor phas-i by the mammalian target of rapamycin","volume":"277","author":"Brunn","year":"1997","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1126\/science.1228792","article-title":"Stimulation of de novo pyrimidine synthesis by growth signaling through mtor and s6k1","volume":"339","author":"Howell","year":"2013","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.1228771","article-title":"Quantitative phosphoproteomics reveal mtorc1 activates de novo pyrimidine synthesis","volume":"339","author":"Robitaille","year":"2013","journal-title":"Science"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mtor complex 1","volume":"39","author":"Duvel","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-nutr-071714-034355","article-title":"The roles of mtor complexes in lipid metabolism","volume":"35","author":"Caron","year":"2015","journal-title":"Annu. Rev. Nutr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"Mtor and cancer: Many loops in one pathway","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200403069","article-title":"The tsc1-2 tumor suppressor controls insulin-pi3k signaling via regulation of irs proteins","volume":"166","author":"Harrington","year":"2004","journal-title":"J. Cell Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mtor-regulated phosphoproteome reveals a mechanism of mtorc1-mediated inhibition of growth factor signaling","volume":"332","author":"Hsu","year":"2011","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies grb10 as an mtorc1 substrate that negatively regulates insulin signaling","volume":"332","author":"Yu","year":"2011","journal-title":"Science"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mtor, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.cub.2006.08.001","article-title":"Msin1 is necessary for akt\/pkb phosphorylation and its isoforms define three distinct mtorc2s","volume":"16","author":"Frias","year":"2006","journal-title":"Curr. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","article-title":"Sin1\/mip1 maintains rictor-mtor complex integrity and regulates akt phosphorylation and substrate specificity","volume":"127","author":"Jacinto","year":"2006","journal-title":"Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/BJ20070540","article-title":"Identification of protor as a novel rictor-binding component of mtor complex-2","volume":"405","author":"Pearce","year":"2007","journal-title":"Biochem. J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.tibs.2016.04.001","article-title":"Torc2 structure and function","volume":"41","author":"Gaubitz","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-15-0460","article-title":"Ptdins(3,4,5)p3-dependent activation of the mtorc2 kinase complex","volume":"5","author":"Liu","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.cell.2011.02.014","article-title":"Activation of mtorc2 by association with the ribosome","volume":"144","author":"Zinzalla","year":"2011","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian tor complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat. Cell Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/ncb2507","article-title":"Prr5l degradation promotes mtorc2-mediated pkc-delta phosphorylation and cell migration downstream of galpha12","volume":"14","author":"Gan","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1083\/jcb.201205030","article-title":"Ablation of the mtorc2 component rictor in brain or purkinje cells affects size and neuron morphology","volume":"201","author":"Thomanetz","year":"2013","journal-title":"J. Cell Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","article-title":"Ablation in mice of the mtorc components raptor, rictor, or mlst8 reveals that mtorc2 is required for signaling to akt-foxo and pkcalpha, but not s6k1","volume":"11","author":"Guertin","year":"2006","journal-title":"Dev. Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"21138","DOI":"10.3390\/ijms160921138","article-title":"Pi3k and akt: Unfaithful partners in cancer","volume":"16","author":"Faes","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"820.e3","DOI":"10.1016\/j.ccell.2017.04.013","article-title":"A pan-cancer proteogenomic atlas of pi3k\/akt\/mtor pathway alterations","volume":"31","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mtor in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Xie, J., Wang, X., and Proud, C.G. (2016). Mtor inhibitors in cancer therapy. F1000Research, 5.","DOI":"10.12688\/f1000research.9207.1"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1726078","DOI":"10.1155\/2017\/1726078","article-title":"Resistance to mtorc1 inhibitors in cancer therapy: From kinase mutations to intratumoral heterogeneity of kinase activity","volume":"2017","author":"Faes","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"Mtor kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An atp-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mtorc1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mtorc2 assembly and akt\/pkb","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mtorc2 loss and uncoupled from longevity","volume":"335","author":"Lamming","year":"2012","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: A new generation of mtor inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase iii trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (radiant-4): A randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase iii study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1111\/febs.12253","article-title":"Mechanisms regulating skeletal muscle growth and atrophy","volume":"280","author":"Schiaffino","year":"2013","journal-title":"FEBS J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1083\/jcb.200903131","article-title":"Muscle inactivation of mtor causes metabolic and dystrophin defects leading to severe myopathy","volume":"187","author":"Risson","year":"2009","journal-title":"J. Cell Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cmet.2008.10.002","article-title":"Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy","volume":"8","author":"Bentzinger","year":"2008","journal-title":"Cell Metab."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ncb1231","article-title":"Atrophy of s6k1(-\/-) skeletal muscle cells reveals distinct mtor effectors for cell cycle and size control","volume":"7","author":"Ohanna","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cmet.2013.03.015","article-title":"Sustained activation of mtorc1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy","volume":"17","author":"Castets","year":"2013","journal-title":"Cell Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ncb1101-1014","article-title":"Akt\/mtor pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo","volume":"3","author":"Bodine","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"9213","DOI":"10.1073\/pnas.142166599","article-title":"A protein kinase b-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification","volume":"99","author":"Pallafacchina","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/jn\/130.10.2413","article-title":"Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive pathway","volume":"130","author":"Anthony","year":"2000","journal-title":"J. Nutr."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"C120","DOI":"10.1152\/ajpcell.1999.276.1.C120","article-title":"Phosphorylation of p70(s6k) correlates with increased skeletal muscle mass following resistance exercise","volume":"276","author":"Baar","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1113\/jphysiol.2007.141507","article-title":"A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy","volume":"586","author":"Spangenburg","year":"2008","journal-title":"J. Physiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1113\/jphysiol.2013.256339","article-title":"Eccentric contractions increase the phosphorylation of tuberous sclerosis complex-2 (tsc2) and alter the targeting of tsc2 and the mechanistic target of rapamycin to the lysosome","volume":"591","author":"Jacobs","year":"2013","journal-title":"J. Physiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/MOL.0b013e328352dd03","article-title":"Connecting mtorc1 signaling to srebp-1 activation","volume":"23","author":"Bakan","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"Srebps: Activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12079-007-0011-1","article-title":"Role of the pi3-kinase\/mtor pathway in the regulation of the stearoyl coa desaturase (scd1) gene expression by insulin in liver","volume":"1","author":"Mauvoisin","year":"2007","journal-title":"J. Cell Commun. Signal."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","article-title":"Srebp activity is regulated by mtorc1 and contributes to akt-dependent cell growth","volume":"8","author":"Porstmann","year":"2008","journal-title":"Cell Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2011.06.002","article-title":"Akt stimulates hepatic srebp1c and lipogenesis through parallel mtorc1-dependent and independent pathways","volume":"14","author":"Yecies","year":"2011","journal-title":"Cell Metab."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.cmet.2012.03.015","article-title":"Hepatic mtorc2 activates glycolysis and lipogenesis through akt, glucokinase and srebp1c","volume":"15","author":"Hagiwara","year":"2012","journal-title":"Cell Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"29579","DOI":"10.1074\/jbc.M112.386854","article-title":"Identification of akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mtor) complex 2","volume":"287","author":"Yuan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"11086","DOI":"10.1073\/pnas.92.24.11086","article-title":"Rapamycin inhibits clonal expansion and adipogenic differentiation of 3t3-l1 cells","volume":"92","author":"Yeh","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Zhang, H.H., Huang, J., Duvel, K., Boback, B., Wu, S., Squillace, R.M., Wu, C.L., and Manning, B.D. (2009). Insulin stimulates adipogenesis through the akt-tsc2-mtorc1 pathway. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006189"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2008.09.003","article-title":"Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration","volume":"8","author":"Polak","year":"2008","journal-title":"Cell Metab."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1254\/jphs.08215FP","article-title":"Rapamycin protects against high fat diet-induced obesity in c57bl\/6j mice","volume":"109","author":"Chang","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue","volume":"59","author":"Houde","year":"2010","journal-title":"Diabetes"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1210\/endo.137.8.8754791","article-title":"Expression of a constitutively activated form of protein kinase b (c-akt) in 3t3-l1 preadipose cells causes spontaneous differentiation","volume":"137","author":"Magun","year":"1996","journal-title":"Endocrinology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1534-5807(02)00401-X","article-title":"The forkhead transcription factor foxo1 regulates adipocyte differentiation","volume":"4","author":"Nakae","year":"2003","journal-title":"Dev. Cell"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"9902","DOI":"10.1073\/pnas.0811321106","article-title":"Mtor complex 2 in adipose tissue negatively controls whole-body growth","volume":"106","author":"Cybulski","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2337\/db09-1061","article-title":"Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism","volume":"59","author":"Kumar","year":"2010","journal-title":"Diabetes"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"ra2","DOI":"10.1126\/scisignal.2003295","article-title":"Bsta promotes mtorc2-mediated phosphorylation of akt1 to suppress expression of foxc2 and stimulate adipocyte differentiation","volume":"6","author":"Yao","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"143S","DOI":"10.1016\/S0041-1345(03)00233-1","article-title":"Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients","volume":"35","author":"Morrisett","year":"2003","journal-title":"Transpl. Proc."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/db09-1602","article-title":"Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis and promotes fat storage","volume":"59","author":"Chakrabarti","year":"2010","journal-title":"Diabetes"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.mce.2012.10.030","article-title":"The immunosuppressive agents rapamycin, cyclosporin a and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue","volume":"365","author":"Pereira","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"R393","DOI":"10.1152\/ajpregu.00716.2007","article-title":"Interleukin-6 and cachexia in apcmin\/+ mice","volume":"294","author":"Baltgalvis","year":"2008","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"White, J.P., Baynes, J.W., Welle, S.L., Kostek, M.C., Matesic, L.E., Sato, S., and Carson, J.A. (2011). The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the apc(min\/+) mouse. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024650"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"E1042","DOI":"10.1152\/ajpendo.00410.2012","article-title":"Muscle mtorc1 suppression by il-6 during cancer cachexia: A role for ampk","volume":"304","author":"White","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13539-011-0047-1","article-title":"The effect of exercise on il-6-induced cachexia in the apc (min\/+) mouse","volume":"3","author":"Puppa","year":"2012","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1096\/fj.13-240580","article-title":"Skeletal muscle glycoprotein 130\u2019s role in lewis lung carcinoma-induced cachexia","volume":"28","author":"Puppa","year":"2014","journal-title":"FASEB J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"C66","DOI":"10.1152\/ajpcell.00052.2015","article-title":"Lewis lung carcinoma regulation of mechanical stretch-induced protein synthesis in cultured myotubes","volume":"310","author":"Gao","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jcsm.12054","article-title":"Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mtor signalling","volume":"7","author":"Chen","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"15790","DOI":"10.1073\/pnas.1521919112","article-title":"Mtor inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy","volume":"112","author":"Zhao","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature18943","article-title":"An evolutionarily conserved pathway controls proteasome homeostasis","volume":"536","author":"Rousseau","year":"2016","journal-title":"Nature"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"26991","DOI":"10.1038\/srep26991","article-title":"Aerobic exercise and pharmacological treatments counteract cachexia by modulating autophagy in colon cancer","volume":"6","author":"Pigna","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cmet.2009.10.008","article-title":"Autophagy is required to maintain muscle mass","volume":"10","author":"Masiero","year":"2009","journal-title":"Cell Metab."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/0008-5472.CAN-11-2739","article-title":"Targeting protein synthesis in a myc\/mtor-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival","volume":"72","author":"Robert","year":"2012","journal-title":"Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13395-016-0098-2","article-title":"Actrii blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments","volume":"6","author":"Hatakeyama","year":"2016","journal-title":"Skelet. Muscle"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3892\/mco.2016.1015","article-title":"Muscle wasting associated with the long-term use of mtor inhibitors","volume":"5","author":"Gyawali","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/8\/2225\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:15:21Z","timestamp":1760195721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/8\/2225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,30]]},"references-count":147,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["ijms19082225"],"URL":"https:\/\/doi.org\/10.3390\/ijms19082225","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,30]]}}}